Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial

Specific Aims Aim 1: To compare the effectiveness of two tobacco treatments that are integrated into cancer care in producing tobacco abstinence at 6 months. Aim 2: To explore: a) mechanisms through which treatment promotes abstinence; b) subpopulations in which abstinence is promoted; and c) which aspects of treatment promote abstinence. Aim 3: To compare the incremental cost effectiveness (cost per quit) of two tobacco treatments. Exploratory Aim: To identify the percentage and associated characteristics of smokers who 1) enroll in tobacco treatment and 2) adhere to tobacco treatment.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Adult men and women may participate in this study if he/she meet the following requirements:
1. Current, new\* patient at one of our three participating study sites: Massachusetts General Hospital (MGH) Cancer Center, Memorial Sloan Kettering Cancer Center (MSKCC), or Dana-Farber Cancer Institute (DFCI);
2. Currently with suspected or newly diagnosed cancer (thoracic, breast, genitourinary, gastrointestinal, head and neck, gynecologic, lymphoma, melanoma);
3. Has smoked a cigarette, even a puff, in the past 30 days;
4. Is willing to consider trying to quit smoking using counseling and/or smoking cessation medication;
5. Is English or Spanish speaking (MGH); English speaking (MSK; DFCI);
6. Has regular telephone access.
\[\*Patients will be considered "new" and eligible under the following conditions:
1. if they are attending approximately one of their first 4 visits or are within approximately 3 months of the initial visit date with their primary oncologist at the Massachusetts General Hospital (MGH) Cancer Center, Memorial Sloan Kettering Cancer Center (MSKCC), or Dana-Farber Cancer Institute (DFCI) for suspected or recently diagnosed cancer;
2. if they come to the MGH, MSKCC, or DFCI for a second opinion, the patient opts to receive their cancer treatment at any of these institutions;
3. if they have a past cancer diagnosis, they are currently faced with a local and distant recurrence of tumors;
4. if they have been treated previously for other types of cancer, they are currently faced with a new form of cancer.\]

You may not be if

In an effort to be as inclusive as possible, a patient will be excluded only if he/she:
1. Is NOT currently receiving or has no intentions to receive care at one of three participating cancer treatment centers: Massachusetts General Hospital Cancer Center, Memorial Sloan Kettering Cancer Center, or Dana-Farber Cancer Institute (DFCI);
2. Is currently psychiatrically unstable or otherwise unable to provide informed consent as determined by study investigators or oncology clinician;
3. Is not English or Spanish speaking;
4. Is medically ineligible (as determined by their treating physician);
5. Has insufficient comprehension/literacy.
ADDITIONAL INFORMATION:
Participant inclusion/exclusion is not based on use of smoking cessation medication -- he/she may decide not to use any smoking cessation medication and still participate in the study. Patients deemed ineligible will be referred to the state quit line.
Patients interested in participating in the study should contact the appropriate contact person, based on whether they are a current patient at the MGH, MSKCC, or DFCI.

Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial

What this study is about

Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial

What this study is about